Intelligence · Clinical Pipeline
Oncology · Phase III
Oncology programs at Phase III — ClinicalTrials.gov pipeline intelligence.
- Programs
- 1,266
Quick answer
Oncology Phase III programs: NovaPharmaNews indexes 1,266 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- AstraZeneca 75 programs
- Chinese Academy of 70 programs
- HOFFMANN-LA ROCHE 68 programs
- MSD Merck Sharp 56 programs
- First People's Hospital 53 programs
- Ningbo Cancer Hospital 44 programs
- United Therapeutics Europe 43 programs
- Anaxis Pharma 37 programs
- AstraZeneca 37 programs
- Novartis India 32 programs
- George Institute for 29 programs
- Takeda 28 programs
-
Taxotere , Epirubicin
Hospital Authority, Hong Kong
Breast Cancer
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
Ningbo Cancer Hospital
High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment.
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
Hoffmann-La Roche
Cancer (Future parent protocols may include other cancer that are not included in this section)
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.
Hoffmann-La Roche
High-risk hepatocellular carcinoma (HCC)
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.
Ningbo Cancer Hospital
Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, CISPLATIN , CARBOPLATIN , BNT327, ETOPOSIDE
BioNTech SE
English First-line extensive-stage small-cell lung cancer (ES-SCLC)
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etoposid Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BI 764532, RoActemra 20 mg/mL concentrate for solution for infusion
Boehringer Ingelheim
small cell lung cancer
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq placebo
Hoffmann-La Roche
Early human epidermal growth factor receptor 2 (HER2) positive breast cancer
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tiragolumab placebo, Tiragolumab
Hoffmann-La Roche
Non-squamous non-small cell lung cancer (NSCLC)
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, LURBINECTEDIN, RO7508182
Hoffmann-La Roche
Small-Cell Lung Cancer (SCLC)
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, PACLITAXEL, CARBOPLATIN
CERO THERAPEUTICS HOLDINGS, INC.
Non Small Cell Lung Cancer
1 trial -
Tecentriq 840 mg concentrate for solution for infusion
Novo Nordisk A/S
Metastatic pancreatic ductal adenocarcinoma (mPDAC)
1 trial -
Tecentriq Placebo, Abraxane 5 mg/ml powder for dispersion for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml Intravenous Infusion, Cisplatin 1mg/ml concentrate for solution for infusion
Hoffmann-La Roche
Early-Stage Resectable Non-small cell lung cancer (NSCLC)
1 trial -
Tecentriq concentrate for solution for infusion placebo 0mg, Tecentriq 840 mg concentrate for solution for infusion
Hoffmann-La Roche
High-risk muscle-invasive bladder cancer
1 trial -
Tegafur-Gimeracil-Oteracil Potassium
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stomach Neoplasm
1 trial -
Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)
Eastern Hepatobiliary Surgery Hospital
Gastric Cancer
1 trial -
Telisotuzumab Adizutecan
AbbVie
Non-Small Cell Lung Cancer
1 trial -
Telisotuzumab Vedotin, DOCETAXEL
AbbVie Deutschland GmbH & Co. KG
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancer
1 trial -
Temomedac 20 mg hard capsules, Temomedac 5 mg hard capsules, Tirabrutinib, Temomedac 100 mg hard capsules, Truxima 500 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion
Lacuna Pharma Pty Ltd
Relapsed/refractory primary central nervous system lymphoma
1 trial -
Thalidomide
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
The placebo tablet composition is: Collodial silicone dioxide, Magnesium stearate, Carmellose sodium, Cellulosa powder. Appearance and size will be the same for active and placebo., Trombyl 160 mg tabletter
The George Institute
Colon and rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTEN
1 trial -
Tiaoshen Anti-cancer Granules
The First People's Hospital of Lianyungang
Ovarian Neoplasms Malignant
1 trial -
Tibsovo 250 mg film-coated tablets
The George Institute
ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma
1 trial -
Tinidazole oral microneedle patch
The First People's Hospital of Lianyungang
Evaluate the DFS of Patients With Esophageal Cancer Who Underwent Radical Operation After Regular Removal of Porphyromonas Gingivalis
1 trial -
Tiragolumab
Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
1 trial -
Tiragolumab Placebo, Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab, Tecentriq Placebo
Hoffmann-La Roche
Unresectable Esophageal Squamous Cell Carcinoma
1 trial -
Tiragolumab, Placebo Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion
Hoffmann-La Roche
Non-small cell lung cancer (NSCLC)
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Classical Hodgkin Lymphoma
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Non Small Cell Lung Cancer
4 trials -
Tislelizumab
BeiGene
Non-small Cell Lung Cancer
2 trials -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colonic Neoplasms
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Urothelial Carcinoma
1 trial -
Tislelizumab
The First People's Hospital of Lianyungang
Rectal Neoplasms
1 trial -
Tislelizumab
BeiGene
Recurrent or Metastatic Nasopharyngeal Cancer
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Locally Advanced Rectal Carcinoma
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Esophageal Squamous Cell Carcinoma (ESCC)
1 trial -
Tislelizumab + SOX Chemotherapy
The First People's Hospital of Lianyungang
Gastric Cancer Stage III
1 trial -
Tislelizumab 300 mg solution for injection, Tevimbra 100 mg concentrate for solution for infusion
BEONE MEDICINES AUS PTY LTD
Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
1 trial -
Tislelizumab(neoadjuvant)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Cell Carcinomas
1 trial -
Topotecan HEXAL 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Anastrozol STADA® 1 mg Filmtabletten, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, VS-6766, LETRO-cell® 2,5 mg Filmtabletten, VS-6063, Letrozol - 1 A Pharma® 2,5 mg Filmtabletten, ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for inf
Vera Therapeutics
Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
1 trial -
Tora-Dol 30 mg/ml soluzione iniettabile, Acido Acetilsalicilico Teva Italia 100 mg compresse gastroresistenti, SODIO CLORURO 0,9% BAXTER Soluzione per infusione
Fondazione Telethon ETS
Patients scheduled for major surgery for oncologic indication
1 trial -
Toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
2 trials -
Toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non Small Cell Lung Cancer
1 trial -
Trabectedin
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ovarian Cancer
1 trial -
Trabectedin EVER Pharma 1 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Pazopanib PharOS 200 mg film-coated tablets, HALAVEN 0.44 mg/ml solution for injection
INTENSITY THERAPEUTICS, INC.
liposarcoma (dedifferentiated, myxoid, round cell or pleomorphic), Leiomyosarcoma (non-uterine), Undifferentiated pleomorphic sarcoma
1 trial -
Trastuzumab
Hoffmann-La Roche
Metastatic Breast Cancer
1 trial -
Trastuzumab
Mylan IRE Healthcare Limited
Breast Cancer
1 trial -
Trastuzumab
Celltrion Healthcare Australia Pty Ltd
HER2-positive Carcinoma of Breast
1 trial
Frequently asked questions
How many oncology Phase III programs exist?
1,266 programs match both the therapeutic area and stage filters in our published index.
Data attribution: Data sources · All pipeline programs